WO2017156514A3 - Methods and agents for modulating cellular metabolism and treating cancer - Google Patents

Methods and agents for modulating cellular metabolism and treating cancer Download PDF

Info

Publication number
WO2017156514A3
WO2017156514A3 PCT/US2017/021993 US2017021993W WO2017156514A3 WO 2017156514 A3 WO2017156514 A3 WO 2017156514A3 US 2017021993 W US2017021993 W US 2017021993W WO 2017156514 A3 WO2017156514 A3 WO 2017156514A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
cellular metabolism
agents
treating cancer
modulating cellular
Prior art date
Application number
PCT/US2017/021993
Other languages
French (fr)
Other versions
WO2017156514A2 (en
Inventor
Hans-Guido Wendel
Kamini SINGH
Yi ZHONG
Gunnar Ratsch
Original Assignee
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memorial Sloan Kettering Cancer Center filed Critical Memorial Sloan Kettering Cancer Center
Publication of WO2017156514A2 publication Critical patent/WO2017156514A2/en
Publication of WO2017156514A3 publication Critical patent/WO2017156514A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/50—Methods for regulating/modulating their activity

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Methods are provided for modulating cellular metabolism by exposing cells to an agent that reduces translation of MYC dependent mRNA transcripts. Such methods and agents are useful for treatment of cancer, and altering cellular metabolism.
PCT/US2017/021993 2016-03-11 2017-03-12 Methods and agents for modulating cellular metabolism and treating cancer WO2017156514A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662307193P 2016-03-11 2016-03-11
US62/307,193 2016-03-11

Publications (2)

Publication Number Publication Date
WO2017156514A2 WO2017156514A2 (en) 2017-09-14
WO2017156514A3 true WO2017156514A3 (en) 2017-10-19

Family

ID=59789747

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2017/021993 WO2017156514A2 (en) 2016-03-11 2017-03-12 Methods and agents for modulating cellular metabolism and treating cancer

Country Status (1)

Country Link
WO (1) WO2017156514A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113599524B (en) * 2021-09-02 2023-05-02 中国医学科学院肿瘤医院 Application of HNRNPC and RBMX as targets in preparation of products for treating small cell lung cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110064739A1 (en) * 2008-03-28 2011-03-17 Borlak Juergen Medicament, compositions, and substances for treating and identifying adenocarcinoma of the lung

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110064739A1 (en) * 2008-03-28 2011-03-17 Borlak Juergen Medicament, compositions, and substances for treating and identifying adenocarcinoma of the lung

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ROMAN ET AL.: "mTFE3, an X-linked transcriptional activator containing basic helix-loop-helix and zipper domains, utilizes the zipper to stabilize both DNA binding and multimerization", MOL CELL BIOL., vol. 12, no. 2, February 1992 (1992-02-01), pages 817 - 827, XP055428974 *

Also Published As

Publication number Publication date
WO2017156514A2 (en) 2017-09-14

Similar Documents

Publication Publication Date Title
PH12020551923A1 (en) Methods and compositions for treating cancer
CL2019000511A1 (en) Inhibitors of cellular metabolic processes.
BR112018067368A2 (en) anti-cd73 antibody combination therapy
MX2020012797A (en) Anti-pvrig/anti-tigit bispecific antibodies and methods of use.
CL2018003316A1 (en) Compounds for the inhibition of k-ras and for the treatment of cancer. (divisional application 201702786)
MX2023007841A (en) Crispr-cpf1-related methods, compositions and components for cancer immunotherapy.
MX2018005315A (en) Compositions and methods for treatment of cancer.
PH12020550901A1 (en) Macrocyclic compounds for treating disease
EP4339287A3 (en) Modified cells and methods of therapy
EA201990296A1 (en) ANTIBODIES AGAINST SIGLEC-7 FOR CANCER TREATMENT
WO2017216772A3 (en) Methods and compositions for treating breast and prostate cancer
BR112018003269A2 (en) anti-dll3 drug-antibody conjugates and methods of use
WO2014164704A3 (en) Compounds and compositions for the treatment of cancer
MX2021005398A (en) Anti-cd33 immune cell cancer therapy.
MX2017010595A (en) Methods, compositions, and kits for treatment of cancer.
EP3581182A4 (en) Combination treating prostate cancer, pharmaceutical composition and treatment method
JOP20190285A1 (en) Use of anti cd70 antibody argx-110 to treat acute myeloid leukaemia
MX2019010040A (en) Compositions and methods for treatment of cancer.
EP3723772A4 (en) Compositions, methods, kits and systems for cancer treatment and metabolic intervention therapy
WO2016160621A3 (en) Nk-92 cells in combination therapy with cancer drugs
PH12017501879A1 (en) Methods for treating cancer
WO2017123568A3 (en) Methods for the treatment of myeloid derived suppressor cells related disorders
IL268163A (en) Methods, compositions, and kits for treatment of cancer
PH12020551543A1 (en) Therapeutic modulators of the reverse mode of atp synthase
MX2021013461A (en) Method of treating lower tract urothelial cancer.

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17764273

Country of ref document: EP

Kind code of ref document: A2

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 31.01.2019)

122 Ep: pct application non-entry in european phase

Ref document number: 17764273

Country of ref document: EP

Kind code of ref document: A2